Filtered By: Scitech
SciTech

Sinopharm’s two COVID-19 shots effective, study says


Two COVID-19 vaccines from China's Sinopharm showed more than 70% efficacy against symptomatic cases, but it remains unclear how much protection they provide against severe or asymptomatic cases, according to the first detailed result of a large late-stage study published to the public.

A vaccine developed by a Wuhan-based subsidiary of Sinopharm was 72.8% effective against symptomatic COVID-19 at least two weeks after second injection, based on interim results, the peer-reviewed study published in the Journal of the American Medical Association showed on Wednesday. The other, according to Bloomberg, was 78.1% effective in preventing symptomatic infections.

According to the Associated Press, Sinopharm and its partners in the Middle East said that the two vaccines—one from the Wuhan Institute of Biological Products and the other from the Beijing Institute of Biological Products—and a placebo were tested on over 40,000 participants in Bahrain, the United Arab Emirates, Egypt and Jordan.

The World Health Organization approved the Sinopharm vaccine for emergency use earlier this month. It is already in use in 42 territories around the world. — Reuters

LOADING CONTENT